Analysts forecast that ANCHIANO THERAP/S (NASDAQ:ANCN) will post ($0.13) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for ANCHIANO THERAP/S’s earnings. The business is expected to report its next earnings results on Monday, March 23rd.
On average, analysts expect that ANCHIANO THERAP/S will report full year earnings of ($1.33) per share for the current financial year, with EPS estimates ranging from ($1.46) to ($1.19). For the next year, analysts anticipate that the business will post earnings of ($0.48) per share, with EPS estimates ranging from ($0.51) to ($0.45). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that cover ANCHIANO THERAP/S.
A number of equities analysts have recently weighed in on the company. Oppenheimer lowered ANCHIANO THERAP/S from an “outperform” rating to a “market perform” rating and set a $16.00 target price on the stock. in a research report on Monday, November 18th. Robert W. Baird downgraded shares of ANCHIANO THERAP/S from an “outperform” rating to a “neutral” rating in a research report on Monday, November 18th. Zacks Investment Research lowered shares of ANCHIANO THERAP/S from a “buy” rating to a “hold” rating in a research note on Tuesday, October 8th. Finally, LADENBURG THALM/SH SH lowered shares of ANCHIANO THERAP/S from a “buy” rating to a “neutral” rating in a research note on Monday, November 18th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. ANCHIANO THERAP/S currently has a consensus rating of “Hold” and a consensus target price of $10.42.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. FMR LLC bought a new stake in ANCHIANO THERAP/S during the 1st quarter worth approximately $288,000. Phoenix Holdings Ltd. purchased a new stake in shares of ANCHIANO THERAP/S in the third quarter worth approximately $57,000. Finally, Virtu Financial LLC bought a new position in shares of ANCHIANO THERAP/S in the third quarter valued at approximately $30,000. 13.29% of the stock is currently owned by institutional investors and hedge funds.
ANCHIANO THERAP/S stock traded down $0.02 during mid-day trading on Friday, reaching $1.59. The stock had a trading volume of 5,220 shares, compared to its average volume of 23,250. The firm has a market capitalization of $11.79 million and a PE ratio of -0.30. ANCHIANO THERAP/S has a fifty-two week low of $1.24 and a fifty-two week high of $11.50. The stock’s 50-day simple moving average is $1.95 and its 200-day simple moving average is $3.07. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.60 and a current ratio of 1.60.
About ANCHIANO THERAP/S
Anchiano Therapeutics Ltd, a clinical-stage biotechnology company, develops gene therapies to treat early-stage bladder cancer. It is primarily developing Inodiftagene that is in various clinical trials for the treatment of non-muscle-invasive bladder cancer. The company was formerly known as BioCancell Ltd.
Further Reading: Gap Up Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ANCHIANO THERAP/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANCHIANO THERAP/S and related companies with MarketBeat.com's FREE daily email newsletter.